Our group reported that SNORD55 was significantly decreased in TEPs of NSCLC patients, especially of early-stage patients; it exerted a promising diagnostic value for NSCLC with an AUC of 0.803 and also improved the diagnostic accuracy of carcinoembryonic antigen (CEA) for tumor progression (62). Here, CEACAM5 is linked to non-small cell lung carcinoma.